These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20667592)

  • 1. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.
    Palacios C; Martín-Pérez R; López-Pérez AI; Pandiella A; López-Rivas A
    Leuk Res; 2010 Nov; 34(11):1533-8. PubMed ID: 20667592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
    Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
    Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
    Richardson PG; Mitsiades CS; Laubach JP; Lonial S; Chanan-Khan AA; Anderson KC
    Br J Haematol; 2011 Feb; 152(4):367-79. PubMed ID: 21219297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of heat shock protein 90 inhibitor 17-dimethylamino-ethylaminogeldanamycin on TNfalpha-mediated apoptosis and TNF-induced NF-kappaB activation].
    Zhong YJ; Wang X; Zheng XL; Yan YY; Liu XM; Liao LC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):303-7. PubMed ID: 21826987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells.
    Palacios C; López-Pérez AI; López-Rivas A
    Cancer Lett; 2010 Jan; 287(2):207-15. PubMed ID: 19632771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hsp90 compromises the DNA damage response to radiation.
    Dote H; Burgan WE; Camphausen K; Tofilon PJ
    Cancer Res; 2006 Sep; 66(18):9211-20. PubMed ID: 16982765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
    Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS
    J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma.
    Davenport EL; Zeisig A; Aronson LI; Moore HE; Hockley S; Gonzalez D; Smith EM; Powers MV; Sharp SY; Workman P; Morgan GJ; Davies FE
    Leukemia; 2010 Oct; 24(10):1804-7. PubMed ID: 20703255
    [No Abstract]   [Full Text] [Related]  

  • 12. The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells.
    Liu KS; Zhang Y; Ding WC; Wang SX; Xiang YF; Yang P; Chen ZP; Zheng K; Liu Z; Xia M; Wang YF
    Int J Oncol; 2012 Dec; 41(6):2276-84. PubMed ID: 23076967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.
    Lukasiewicz E; Miekus K; Kijowski J; Gozdzik J; Wilusz M; Bobis-Wozowicz S; Wiecha O; Majka M
    J Physiol Pharmacol; 2009 Sep; 60(3):161-6. PubMed ID: 19826195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
    Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma therapies.
    Strobeck M
    Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
    [No Abstract]   [Full Text] [Related]  

  • 19. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
    Archer CR; Koomoa DL; Mitsunaga EM; Clerc J; Shimizu M; Kaiser M; Schellenberg B; Dudler R; Bachmann AS
    Biochem Pharmacol; 2010 Jul; 80(2):170-8. PubMed ID: 20362557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
    Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
    Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.